Rani Therapeutics Collaborates with ProGen to Develop RT-114 for Obesity
Shots:
- Rani & ProGen have partnered to co-develop & commercialize RT-114 (ProGen’s PG-102 contained in RaniPill capsule) for obesity
- Both of them will share global development & commercialization of RT-114, with a 50/50 cost & revenue split. Rani will conduct preclinical & P-I study (starting in 2025) plus gain exclusive rights in the US, EU, Canada & Australia with ProGen covering ROW. Upfront financial exchange is not involved
- In addition, PG-102 (GLP-1/GLP-2 dual agonist) showed a good safety profile with fewer GI side effects vs other programs under its P-I trial (Korea). PK/PD data & preclinical results further suggest weekly to monthly dosing of RT-114, improving patient adherence
Ref: Rani Therapeutics | Image: Rani Therapeutics
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
